Limits...
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Higuchi T, Briley M - Neuropsychiatr Dis Treat (2007)

Bottom Line: As such it has attracted relative little interest from clinician investigators as a research tool.Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced).This article reviews these Japanese studies with milnacipran.

View Article: PubMed Central - PubMed

Affiliation: Musashi Hospital, National Centre for Neurology and Psychiatry, Tokyo, Japan.

ABSTRACT
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI), with a balanced potency for the inhibition of the reuptake of the two monoamines. In this, it contrasts with venlafaxine and duloxetine which, while possessing a dual action, have a selectivity of the order of 30-fold and 10-fold respectively for the reuptake of serotonin. Milnacipran has mainly been launched in countries where the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine had been established for several years. As such it has attracted relative little interest from clinician investigators as a research tool. Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced). This has led to a large number of investigative clinical studies, many of which give interesting insights into the potential of milnacipran in the treatment of depression and of other disorders. This article reviews these Japanese studies with milnacipran.

No MeSH data available.


Related in: MedlinePlus

Response to milnacipran in patients stratified by severity. Severity was defined by baseline MADRS; Severe = MADRS ≥ 31; moderate = MADRS 25–30; mild = MADRS 21–24; Response = reduction ≥50% of the baseline MADRS; Drawn from data from Sugawara et al (2006).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2654524&req=5

f1-ndt-3-41: Response to milnacipran in patients stratified by severity. Severity was defined by baseline MADRS; Severe = MADRS ≥ 31; moderate = MADRS 25–30; mild = MADRS 21–24; Response = reduction ≥50% of the baseline MADRS; Drawn from data from Sugawara et al (2006).

Mentions: In another study, 80 Japanese patients with major depressive disorders were stratified by severity according to their baseline Montgomery-Asberg Depression Rating Score (MADRS): “severe” MADRS ≥31 (n = 25); “moderate” MADRS = 25–30 (n = 30) and “mild” MADRS = 21–24 (n = 25) (Sugawara et al 2006). “Severe” and “moderate” patients had more melancholia than “mild” patients (17, 6, and 1 patient respectively). Milnacipran was administered twice daily for 6 weeks at an initial dose of 50 mg/d for the first week and then 100 mg/d. Mean plasma levels of milnacipran were similar in the “severe” and “mild” groups but significantly higher in the “moderate” group. The response rates were 72%, 70%, and 44% in the “severe,” “moderate,” and “mild,” categories respectively (Figure 1). The differences between “severe” and “mild” and “moderate” and “mild” were significant whereas the difference between severe and moderate was not. This study suggests that milnacipran may be more effective in treating patients with moderate and severe major depression compared to those with mild depression.


Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Higuchi T, Briley M - Neuropsychiatr Dis Treat (2007)

Response to milnacipran in patients stratified by severity. Severity was defined by baseline MADRS; Severe = MADRS ≥ 31; moderate = MADRS 25–30; mild = MADRS 21–24; Response = reduction ≥50% of the baseline MADRS; Drawn from data from Sugawara et al (2006).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2654524&req=5

f1-ndt-3-41: Response to milnacipran in patients stratified by severity. Severity was defined by baseline MADRS; Severe = MADRS ≥ 31; moderate = MADRS 25–30; mild = MADRS 21–24; Response = reduction ≥50% of the baseline MADRS; Drawn from data from Sugawara et al (2006).
Mentions: In another study, 80 Japanese patients with major depressive disorders were stratified by severity according to their baseline Montgomery-Asberg Depression Rating Score (MADRS): “severe” MADRS ≥31 (n = 25); “moderate” MADRS = 25–30 (n = 30) and “mild” MADRS = 21–24 (n = 25) (Sugawara et al 2006). “Severe” and “moderate” patients had more melancholia than “mild” patients (17, 6, and 1 patient respectively). Milnacipran was administered twice daily for 6 weeks at an initial dose of 50 mg/d for the first week and then 100 mg/d. Mean plasma levels of milnacipran were similar in the “severe” and “mild” groups but significantly higher in the “moderate” group. The response rates were 72%, 70%, and 44% in the “severe,” “moderate,” and “mild,” categories respectively (Figure 1). The differences between “severe” and “mild” and “moderate” and “mild” were significant whereas the difference between severe and moderate was not. This study suggests that milnacipran may be more effective in treating patients with moderate and severe major depression compared to those with mild depression.

Bottom Line: As such it has attracted relative little interest from clinician investigators as a research tool.Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced).This article reviews these Japanese studies with milnacipran.

View Article: PubMed Central - PubMed

Affiliation: Musashi Hospital, National Centre for Neurology and Psychiatry, Tokyo, Japan.

ABSTRACT
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI), with a balanced potency for the inhibition of the reuptake of the two monoamines. In this, it contrasts with venlafaxine and duloxetine which, while possessing a dual action, have a selectivity of the order of 30-fold and 10-fold respectively for the reuptake of serotonin. Milnacipran has mainly been launched in countries where the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine had been established for several years. As such it has attracted relative little interest from clinician investigators as a research tool. Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced). This has led to a large number of investigative clinical studies, many of which give interesting insights into the potential of milnacipran in the treatment of depression and of other disorders. This article reviews these Japanese studies with milnacipran.

No MeSH data available.


Related in: MedlinePlus